drugset / Trial / NCT00390936
A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the dose limiting toxicity (DLT) of BMS-582664 and the maximum tolerated dose(MTD) in subjects with advanced or metastatic solid tumors.
Timeline
- Start
- 2007-10
- Primary completion
- 2010-03
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Brivanib | Small molecule | 300 mg | Oral |
| Comparator | Brivanib | Small molecule | 600 mg | Oral |
| Comparator | Brivanib | Small molecule | 800 mg | Oral |
| Comparator | Brivanib | Small molecule | 1000 mg | Oral |